CN113121413B - 一种jak3酶抑制剂关键中间体的制备方法 - Google Patents
一种jak3酶抑制剂关键中间体的制备方法 Download PDFInfo
- Publication number
- CN113121413B CN113121413B CN201911417506.1A CN201911417506A CN113121413B CN 113121413 B CN113121413 B CN 113121413B CN 201911417506 A CN201911417506 A CN 201911417506A CN 113121413 B CN113121413 B CN 113121413B
- Authority
- CN
- China
- Prior art keywords
- compound
- ethanol
- solution
- solvent
- mass
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 title claims abstract description 7
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 title claims abstract description 6
- 229940125532 enzyme inhibitor Drugs 0.000 title claims abstract description 6
- 239000002532 enzyme inhibitor Substances 0.000 title claims abstract description 6
- 238000002360 preparation method Methods 0.000 title abstract description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims abstract description 26
- 238000006243 chemical reaction Methods 0.000 claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 15
- 239000002904 solvent Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 11
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 9
- JKSBJAIJUUQUJS-WCQYABFASA-N (3R,6S)-1-benzyl-6-methylpiperidin-3-amine Chemical compound C[C@H]1CC[C@@H](N)CN1Cc1ccccc1 JKSBJAIJUUQUJS-WCQYABFASA-N 0.000 claims abstract description 8
- 239000002244 precipitate Substances 0.000 claims abstract description 8
- 230000000707 stereoselective effect Effects 0.000 claims abstract description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 5
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims abstract description 3
- 238000002156 mixing Methods 0.000 claims abstract description 3
- 150000003839 salts Chemical class 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 47
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 39
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- 229940126214 compound 3 Drugs 0.000 claims description 14
- 229940125898 compound 5 Drugs 0.000 claims description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- 238000003786 synthesis reaction Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 claims description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 239000007810 chemical reaction solvent Substances 0.000 claims description 4
- CMIBUZBMZCBCAT-HZPDHXFCSA-N (2r,3r)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HZPDHXFCSA-N 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 229940125904 compound 1 Drugs 0.000 claims description 2
- 229940125782 compound 2 Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 238000001308 synthesis method Methods 0.000 claims 5
- 238000010189 synthetic method Methods 0.000 claims 1
- UENBBJXGCWILBM-UHFFFAOYSA-N 6-methylpyridin-3-amine Chemical compound CC1=CC=C(N)C=N1 UENBBJXGCWILBM-UHFFFAOYSA-N 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 239000007858 starting material Substances 0.000 abstract 1
- 238000003756 stirring Methods 0.000 description 13
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 235000011181 potassium carbonates Nutrition 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- GLNZGGFNQUSLIJ-UHFFFAOYSA-N tert-butyl n-(6-methylpyridin-3-yl)carbamate Chemical compound CC1=CC=C(NC(=O)OC(C)(C)C)C=N1 GLNZGGFNQUSLIJ-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- -1 (6-methylpyridin-3-yl) tert-butyl Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- UXLDFTUCNFDMOT-UHFFFAOYSA-N 2,3-dihydroxy-2-(2-methylbenzoyl)butanedioic acid Chemical compound CC1=CC=CC=C1C(=O)C(O)(C(O)C(O)=O)C(O)=O UXLDFTUCNFDMOT-UHFFFAOYSA-N 0.000 description 1
- OOKSMYZBWRKRGU-UHFFFAOYSA-N 2-benzoyl-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)C(=O)C1=CC=CC=C1 OOKSMYZBWRKRGU-UHFFFAOYSA-N 0.000 description 1
- 230000035502 ADME Effects 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- 108010019421 Janus Kinase 3 Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- RPNNPZHFJPXFQS-UHFFFAOYSA-N methane;rhodium Chemical compound C.[Rh] RPNNPZHFJPXFQS-UHFFFAOYSA-N 0.000 description 1
- NCPHGZWGGANCAY-UHFFFAOYSA-N methane;ruthenium Chemical compound C.[Ru] NCPHGZWGGANCAY-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
本发明涉及一种JAK3酶抑制剂关键中间体((3R,6S)‑1‑苄基‑6‑甲基哌啶‑3‑胺)的制备方法,具体而言,以6‑甲基吡啶‑3‑胺为起始原料,经过Boc保护,催化氢化,苄基保护,三氟乙酸脱Boc保护,成盐拆分,游离得到所需的中间体。所述成盐拆分方法通过在溶剂中将含有该式结构的化合物对映体的外消旋混合物与具有明确立体特异性的拆分试剂混合以形成一种溶液,所述拆分剂能够结合至少一种但不是所有所述对映体以形成含有所述至少一种所述立体特异性形式的对映体的沉淀;收集沉淀并将其纯化,或者收集含有其他所述对映体的溶液,并重结晶该溶液中包含的对映体。本发明原料价廉易得,反应条件温和,反应可控性高,具有良好的工业化应用前景。
Description
技术领域
本发明涉及医药领域,具体而言涉及一种JAK3酶抑制剂关键中间体(纯对映异构体(3R,6S)-1-苄基-6-甲基哌啶-3-胺)的制备方法。
背景技术
PF-06651600是辉瑞公司研究开发的一个高选择性的口服生物利用Janus激酶3(JAK3)抑制剂,代表一种潜在的免疫调节治疗。由于其良好的疗效、安全性和ADME特性,这种JAk3特异性共价抑制剂已被用于斑秃、类风湿关节炎、克罗恩病和溃疡性结肠炎的治疗。2018年9月5日,在一项二期研究的积极结果的支持下, FDA授予PF-06651600治疗斑秃的“突破疗法”称号。
专利WO2015/083028中公开了该化合物的制备方法,其中与本发明相关的制备方法具体如下:
专利路线中获得手性纯关键中间体的方法是通过手性色谱分离,且只能得到含有目标物的对映异构体混合物,收率低,成本高,不适于大规模生产。
鉴于此,急需开发一种新的,操作简单、经济环保的合成PF06651600关键中间体((3R,6S)-1-苄基-6-甲基哌啶-3-胺)的方法。
发明内容
本申请提供了一种制备JAK3酶抑制剂关键中间体((3R,6S)-1-苄基-6-甲基哌啶-3-胺)的方法,包括以下步骤:
(1)化合物2经过Boc保护,得到化合物3;
(2)化合物3经过催化氢化,得到化合物4;
(3)化合物4经过苄基保护,得到化合物5;
(4)化合物5经过脱Boc保护,得到化合物6;
(5)化合物6依次经过成盐拆分,游离,得到化合物1;
在一些实施例方案中,步骤(1)中反应溶剂为乙醇、甲醇、异丙醇、正丁醇、四氢呋喃、乙腈、二氯甲烷等,优选乙醇;纯化溶剂为乙酸乙酯、乙酸异丙酯、乙酸正丁酯和正己烷、正庚烷的两者组合,优选乙酸乙酯和正己烷。
在一个具体的实施例中,步骤(1)中的反应溶剂为乙醇,纯化溶剂为乙酸乙酯和正己烷
步骤(2)中的催化剂为钯碳、氢氧化钯碳、钌碳、铑碳、二氧化铂等,优选为二氧化铂;溶剂为乙酸、乙醇、甲醇等一种或两种的组合,优选乙酸和乙醇的混合溶剂 ;化合物3与催化剂的质量比为1:0.01~0.10,优选为1:0.05;化合物3与乙酸质量体积比为1:0.5~10,化合物3与乙醇的质量体积比为1:5~20,优选为化合物3与乙酸,乙醇质量体积比为1:1:10;反应温度为40~65℃,优选为50~60℃;氢气环境压力为40~70psi,优选为50psi。步骤(2)中所用溶剂为甲醇,乙醇,四氢呋喃等中的一种或两种混合溶剂,优选为甲醇。
在一个具体的实施例中,步骤(2)中的溶剂为甲醇,催化剂为二氧化铂,化合物4和催化剂的质量比为1:0.05,化合物3与乙酸,乙醇质量体积比为1:1:10,反应温度为50~60℃,氢气环境压力为50psi。
步骤(3)中所用保护基为苄基;缚酸剂为碳酸钾,碳酸钠,碳酸铯,碳酸氢钠,碳酸氢钾,优选碳酸钾。
在一个具体的实施例中,步骤(3)中的所用保护基为苄基,缚酸剂为碳酸钾
步骤(4)中所用溶剂为二氯甲烷、三氯甲烷、四氯化碳、1,2-二氯乙烷等,优选二氯甲烷;脱保护剂为三氟乙酸;化合物5与二氯甲烷的质量体积比(g:ml)为1:3~20,优选1:5;化合物5与三氟乙酸的摩尔比为1:5~20,优选为1:10;滴加三氟乙酸温度为0~30℃,优选为0~5℃,反应温度为20~30℃。
在一个具体的实施例中,步骤(4)中的溶剂为二氯甲烷;脱保护剂为三氟乙酸;化合物5和二氯甲烷的质量体积比(g:ml)为1:5;化合物5与三氟乙酸摩尔比为1: 10,滴加三氟乙酸温度为0~5℃,反应温度为20~30℃。
步骤(5)中所述方法包括步骤:
a)在溶剂中将含有所述化合物6的消旋混合物与具有明确立体特异性的拆分试剂混合以形成一种溶液,所述拆分剂能够结合至少一种但不是所有所述对映体以形成含有所述至少一种所述对映体的沉淀;
b)使该混合物静置一段充足的时间以允许从溶液中大体上沉淀外消旋混合物中的一种立体特异性对映体,而所述对映体中的另一种留在所述溶液中;和
c)根据期望的化合物的立体特异性对映体,收集沉淀并将其纯化;或者收集含有另一种所述对映体的溶液,并重结晶该溶液中含有的对映体。
其中该拆分试剂选自酒石酸及其衍生物,扁桃酸及其衍生物,樟脑磺酸及其衍生物和腺酸及其衍生物。
其中该酒石酸衍生物包括立体特异性构象的甲苯酰基酒石酸和苯甲酰基酒石酸,优选为二-对甲苯酰基-L-酒石酸。
其中该溶剂选自甲醇、乙醇、异丙醇、乙腈,四氢呋喃水、甲苯、乙酸乙酯、二氯甲烷及其混合物,优选乙醇和水的混合物。
在一个具体的实施例中,步骤(5)中的成盐溶剂为乙醇和水;拆分试剂为二-对甲苯酰基-L-酒石酸。
优势:
本发明原料价廉易得,反应条件温和,反应可控性高;确定一种可放大的经典拆分方法,以在合成早期分离富含对映体的中间体,从而避免后期多次手性色谱分离。具有良好的工业化应用前景。
具体实施方式:
下面通过实施例对本发明进行具体的描述,有必要再次指出的是以下实施例只用于对本发明进行进一步说明,不能理解为对本发明保护范围的限制
(6-甲基吡啶-3-基)氨基甲酸叔丁酯(3)的合成
在1000ml的三口瓶中,加入6-甲基吡啶-3-胺(80.00g,739.75mmol,1.0eq),乙醇(320ml),降温至0℃搅拌。缓慢滴加(Boc)2O(209.89g,209.89mol,1.3eq),滴加完全,转移至室温搅拌过夜。TLC监测(PE/EA=3:1),反应完全,减压过滤,少量无水乙醇洗涤滤饼,滤液减压浓缩得油状物粗品。
粗品转移至2000ml的三口瓶中,加入乙酸乙酯(160ml),正己烷(800ml),升温至60℃搅拌,体系澄清,停止加热,自然降温,,有黄色固体析出,室温搅拌过夜,降温至5-10℃,搅拌1h,减压抽滤,少量正己烷洗涤滤饼,抽干,60℃鼓风干燥8h,得到黄色固体粉末(6-甲基吡啶-3-基)氨基甲酸叔丁酯(112.20g,72.8%)。
外消旋-顺式/反式-(6-甲基哌啶-3-基)氨基甲酸叔丁酯(4)的合成
在2000ml的氢化釜中,氮气置换三次,氮气环境下,加入(6-甲基吡啶-3-基)氨基甲酸叔丁酯(110.00g,528.18mmol,1.0eq),二氧化铂(5.50g,5%w/w),乙酸(110ml),乙醇(1100ml),氢气置换3-4次,保持在氢气环境(50psi)下,升温至外温50-60℃反应12h。TLC监测(PE/EA=3:1),反应完全,停止加热,降温至室温,氮气置换3次,减压过滤,无水乙醇洗涤滤饼,滤液减压浓缩得油状外消旋-顺式/反式-(6-甲基哌啶-3-基)氨基甲酸叔丁酯(113.00g,99.8%)。
外消旋-顺式/反式-(1-苄基-6-甲基哌啶-3-基)氨基甲酸叔丁酯(5)的合成
在3000ml的三口瓶中,加入外消旋-顺式/反式-(6-甲基哌啶-3-基)氨基甲酸叔丁酯(110.00g,513.28mmol,1.0eq),碳酸钾(212.81g,1.54 mol,3.0eq),干燥的DMF(1100ml),室温下搅拌30min,滴加苄氯(74.72g,590.27mmol,1.15eq)。滴加完全,升温至65℃反应12h,TLC监测(PE/EA=3:1),碘显色反应完全,停止加热,室温搅拌过夜。,转移至10L的反应釜中,加入水(3300ml)稀释。搅拌下加入EA(1100mlx3)萃取,有机相合并,用半饱和食盐水(1100ml*2)洗涤两次,无水硫酸钠干燥,有机相减压浓缩得油状物外消旋-顺式/反式-(1-苄基-6-甲基哌啶-3-基)氨基甲酸叔丁酯(156.26g,100.0%)。
外消旋-顺式/反式-1-苄基-6-甲基哌啶-3-胺(6)的合成
在2000ml的三口瓶中,加入外消旋-顺式/反式-(1-苄基-6-甲基哌啶-3-基)氨基甲酸叔丁酯(135.00g,443.45mmol,1.0eq),二氯甲烷(675ml),搅拌下降温至0℃,控制内温0-5℃,滴加三氟乙酸(505.63g,4.43mol,10.0eq)。滴加完全,自然升温至室温搅拌过夜。TLC监测(PE/EA=3:1),反应完全,转移至5L三口瓶,加入二氯甲烷(675ml)稀释。搅拌下降温至0℃,控制内温0~10℃,滴加配制好的2N的氢氧化钠(2218ml),滴加完全,停止降温,升温至室温搅拌30min,分液,有机相用水(675ml)洗涤一次,饱和食盐水(675ml)洗涤一次,无水硫酸钠干燥,有机相减压浓缩得油状物外消旋-顺式/反式-1-苄基-6-甲基哌啶-3-胺(83.00g,91.6%)。
(3R,6S)-1-苄基-6-甲基哌啶-3-胺(1)的合成
将外消旋-顺式/反式-1-苄基-6-甲基哌啶-3-胺(80.00g, 391.55m mol,1.0eq),溶清于乙醇/水(800ml/800ml),随后往其中加入二对甲基苯甲酰酒石酸(75.64g,195.77mmol,0.5eq),搅拌加热至体系回流,体系澄清,降温至70℃保温搅拌,有固体逐渐析出。TLC检测,反应完毕,缓慢降温至20℃,抽滤,少量乙醇/水(80ml/80ml)洗涤滤饼,滤饼抽干。置于的水(1600ml)中,加热至60~65℃,搅拌溶清,然后滴加2M氢氧化钠溶液调节pH在9~10,搅拌充分后用乙酸乙酯萃取(800ml×2),合并有机相,用饱和氯化钠溶液(600ml)洗涤一次,无水硫酸钠干燥,过滤,减压浓缩至干,得到(3R,6S)-1-苄基-6-甲基哌啶-3-胺24.80g,收率31.0%。1H-NMR(400MHz,DMSO-d6)δ(ppm)7.28~7.32(m,4H),7.19~7.25(m,1H),3.64(d,1H),3.40(d,1H),2.63~2.70(m,2H),2.21~2.30(m,2H),1.44~1.64(m,3H),1.24~1.36(m,1H),1.01(d,3H);[M+H]+=205.2;手性HPLC检测纯度99%。
Claims (12)
1.一种制备JAK3酶抑制剂关键中间体(3R,6S)-1-苄基-6-甲基哌啶-3-胺的方法,包括以下步骤:
(1)化合物2经过Boc保护,得到化合物3;
(2)化合物3经过催化氢化,得到化合物4;
(3)化合物4经过苄基保护,得到化合物5;
(4)化合物5经过脱Boc保护,得到化合物6;
(5)化合物6依次经过成盐拆分,游离,得到化合物1;
步骤(5)中所述方法具体包括步骤:
(a)在溶剂中将含有所述化合物6的消旋混合物与具有明确立体特异性的拆分试剂混合以形成一种溶液,所述拆分剂能够结合至少一种但不是所有所述对映体以形成含有所述至少一种所述对映体的沉淀;
(b)使该混合物静置一段充足的时间以允许从溶液中大体上沉淀外消旋混合物中的一种立体特异性对映体,而所述对映体中的另一种留在所述溶液中;和
(c)根据期望的化合物的立体特异性对映体,收集沉淀并将其纯化;或者收集含有另一种所述对映体的溶液,并重结晶该溶液中含有的对映体;
所述步骤(5)拆分试剂为二-对甲苯酰基-L-酒石酸;
所述步骤(5)溶剂选自乙醇和水的混合物。
2.如权利要求1所述的合成方法,其特征在于步骤(1)中的反应溶剂为乙醇、甲醇、异丙醇、正丁醇、四氢呋喃、乙腈、二氯甲烷;纯化溶剂为乙酸乙酯和正己烷。
3.如权利要求2所述的合成方法,其特征在于步骤(1)中的反应溶剂为乙醇。
4.如权利要求1所述的合成方法,其特征在于步骤(2)中的溶剂为乙酸和乙醇的混合溶剂;化合物3与催化剂的质量比为1:0.01~0.10;化合物3与乙酸质量体积比为1:0.5~10,化合物3与乙醇的质量体积比为1:5~20;反应温度为40~65℃;氢气压力为40~70psi。
5.如权利要求4所述的合成方法,其特征在于步骤(2)中化合物3与催化剂二氧化铂的质量比为1:0.05。
6.如权利要求4所述的合成方法,其特征在于步骤(2)中化合物3与乙酸、乙醇质量体积比为1:1:10。
7.如权利要求4所述的合成方法,其特征在于步骤(2)中反应温度为50~60℃。
8.如权利要求4所述的合成方法,其特征在于步骤(2)中氢气压力为50psi。
9.如权利要求1所述的合成方法,其特征在于步骤(4)中化合物5与二氯甲烷的质量体积比为每g化合物5使用3~20ml的二氯甲烷;化合物5与三氟乙酸的摩尔比为1:5~20;滴加三氟乙酸温度为0~30℃;反应温度为20~30℃。
10.如权利要求9所述的合成方法,其特征在于步骤(4)中化合物5与二氯甲烷的质量体积比为每g化合物5使用5ml的二氯甲烷。
11.如权利要求9所述的合成方法,其特征在于步骤(4)中化合物5与三氟乙酸的摩尔比为1:10。
12.如权利要求9所述的合成方法,其特征在于步骤(4)中滴加三氟乙酸温度为0~5℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911417506.1A CN113121413B (zh) | 2019-12-31 | 2019-12-31 | 一种jak3酶抑制剂关键中间体的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911417506.1A CN113121413B (zh) | 2019-12-31 | 2019-12-31 | 一种jak3酶抑制剂关键中间体的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113121413A CN113121413A (zh) | 2021-07-16 |
CN113121413B true CN113121413B (zh) | 2024-04-09 |
Family
ID=76770657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911417506.1A Active CN113121413B (zh) | 2019-12-31 | 2019-12-31 | 一种jak3酶抑制剂关键中间体的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113121413B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106061973A (zh) * | 2013-12-05 | 2016-10-26 | 辉瑞公司 | 吡咯并[2,3‑d]嘧啶基、吡咯并[2,3‑b]吡嗪基和吡咯并[2,3‑d]吡啶基丙烯酰胺 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012506375A (ja) * | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 2,5−二置換ピペリジンオレキシン受容体アンタゴニスト |
-
2019
- 2019-12-31 CN CN201911417506.1A patent/CN113121413B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106061973A (zh) * | 2013-12-05 | 2016-10-26 | 辉瑞公司 | 吡咯并[2,3‑d]嘧啶基、吡咯并[2,3‑b]吡嗪基和吡咯并[2,3‑d]吡啶基丙烯酰胺 |
Non-Patent Citations (1)
Title |
---|
Process Development and Scale Up of a Selective JAK3 Covalent Inhibitor PF-06651600;Yong Tao et al.;《Organic Process Research & Development》;第23卷;第1872-1880页 * |
Also Published As
Publication number | Publication date |
---|---|
CN113121413A (zh) | 2021-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004011463A1 (en) | Modified pictet-spengler reaction and products prepared therefrom | |
EP2462107A1 (en) | Solid forms of an n-(phenylmethyl)propanamide derivative and processes of preparation | |
EP2327708A2 (en) | Purification method for adefovir dipivoxil | |
CN110590635A (zh) | 左乙拉西坦及其中间体的制备方法 | |
CN116640088A (zh) | 一种高纯度雷芬那辛的制备方法 | |
CN106977415B (zh) | 一种沙库必曲的中间体及其制备方法 | |
KR20120039344A (ko) | 엔독시펜의 신규한 제조 방법 | |
EP2914574B1 (en) | New process | |
Anderson et al. | The preparation of β-substituted amines from mixtures of epoxide opening products via a common aziridinium ion intermediate | |
CN113121413B (zh) | 一种jak3酶抑制剂关键中间体的制备方法 | |
CN116751136A (zh) | 氧代吡啶类化合物的新型制备方法及关键中间体 | |
CN105523957B (zh) | 一锅法制备拉科酰胺的方法 | |
WO2014035107A1 (ko) | 플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법 | |
CN109265385B (zh) | 一种手性催化剂的合成工艺 | |
EP1817273B1 (en) | Method for preparing diastereoisomers of 4-hydroxy isoleucine | |
CN114671891A (zh) | 一种依维莫司乙基化杂质的制备方法 | |
CN108203396B (zh) | 一种脑啡肽酶抑制剂的合成 | |
CN111362935A (zh) | N-羟基托烷司琼的合成方法 | |
JP4861317B2 (ja) | 2,3−ジアミノプロピオン酸誘導体のエナンチオマー体の製造方法。 | |
CN112266381B (zh) | 一种巴洛沙韦中间体的合成新方法 | |
CN115286504B (zh) | 一种合成(r)-2-(2-(叔丁氧基)-2-氧乙基)戊酸的方法 | |
CN112824381B (zh) | 一种哌啶胺的制备方法 | |
CN117447387A (zh) | 一种利特昔替尼关键中间体的制备方法 | |
CN109912426B (zh) | 用于合成抗艾滋病药物增强剂可比司他(cobicistant)的中间体 | |
CN115246784A (zh) | 乌帕替尼中间体化合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |